Ranibizumab

It is a recombinat humanized IgGI kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). It is antineovascularisation agent.

Indications

Wet age-related macular degeneration (wet AMD), macular edema following retinal vein occlusion (RVO), and diabetic macular edema (DME).

Dosage

Intraocular injection; 0.5mg.

Contra-Indications

Hypersensitivity, Ocular infection, intraocular inflammation.

Special Precautions

Paediatric: Not recommended. Pregnancy: Wait at least 3 months after last dose before conceiving a child. Lactation: Not recommended. Elderly: safe.

Side Effects

Endophthalmitis retinal detachments, and iatrogenic traumatic cataracts, hypertension/elevated blood pressure, nasopharyngitis, arthralgia, headache, bronchitis, cough, anemia, nausea, sinusitis, influenza.

Drug Interactions

With verteporfin photodynamic therapy intraocular inflammation is seen.